AKTS Aktis Oncology, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$19.48

Period return

-2.92 (-13.04%)

Volume

97.9K

2026-06-01O $20.59 H $20.61 L $19.48 C $19.48MA5 $20.23MA20 $19.46MA60 $18.86

6M · 98 barsYahoo Finance · USD2026-01-09 → 2026-06-01

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 04. 29.MediumBUYlast month
William Blair: Outperform
US analyst rating / recommendation change.
2026. 03. 31.LowBUY2 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 03. 09.MediumBUY3 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $32.25 · 5 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
HQ: Boston, MA, United States
Fiscal year end: —
Employees: 79
IPO date: —

View details →

2026. 02. 03.MediumBUY4 months ago

Leerink Partners: Outperform